Summary
Key results
Real-time, automated analysis of images from dPCR instruments
Support for core dPCR functions: quantification, mutation detection, CNV analysis, and gene expression analysis
Manual interpretation undermined speed and accuracy
QIAGEN laboratories analyze thousands of DNA samples daily; every minute of delay extends diagnostic timelines and increases research costs. Manual interpretation of images from dPCR devices was time-consuming, error-prone, and dependent on operator experience. The company needed a solution to automate analysis, ensure globally consistent results, and enable development of new molecular assays – especially in oncology and targeted therapies.
Image-analysis and statistical-computing application
The transformation aimed to establish a consistent IT–business collaboration model and rationalize tooling so teams could operate in a transparent, repeatable, and scalable way. Sii Poland adopted a dual-track approach, addressing process and tooling in parallel.
Sii experts:
- Designed an architecture enabling real-time image processing via data streaming from laboratory instruments
- Built a fluorescence-analysis module that automatically detects and classifies signals from DNA samples
- Implemented a computation engine in Java and .NET for noise filtering, statistical analysis, and target concentration calculations
- Delivered an intuitive React.js user interface with results visualizations and data export for downstream analysis
- Created a modular architecture that simplifies adding new capabilities, including mutation detection, copy number variation (CNV) analysis, and gene expression analysis
This end-to-end approach provided QIAGEN with a stable, scalable, and fully automated tool that supports daily laboratory workflows and the development of new diagnostic tests.
Faster studies, more accurate results, stronger market position
With Sii’s application, DNA analysis at QIAGEN now runs faster, more accurately, and fully automatically. Processing and interpretation time dropped from many hours to mere tens of minutes, while eliminating human error ensured repeatable results across laboratories worldwide.
Researchers can validate hypotheses and develop diagnostic assays much faster, accelerating the introduction of new disease-detection methods – especially for cancer and genetic disorders. In turn, patients receive accurate diagnoses sooner and gain access to targeted therapies tailored to their genetic profile.
The project increased R&D efficiency and reinforced QIAGEN’s position as a global leader in dPCR technology and molecular diagnostics.